Loading stock…

Arcus Biosciences, Inc. (RCUS) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Arcus Biosciences, Inc.

RCUSMarket cap $3.12BPrice $24.5

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops cancer immunotherapies designed to help the immune system attack tumors more effectively. Its lead drug, domvanalimab, is in late-stage trials through a major partnership with Gilead, betting big on next-gen checkpoint inhibitors.

In Bastion Portfolios?

52W Return+49%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+30%10

Revenue Forecast

Rev CAGR (1y)-70%1

Rev CAGR (3y)-24%1

Rev CAGR (5y)+24%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Margin-415%1

Net Income Margin-393%1

Free Cash Flow Margin-406%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-91%1

ROA-46%1

Earnings Stabilityna–

GEAR+VERY WEAK2

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV6.72

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-15.2%1

Dividend Yieldna–

Momentum

Short term

1 month return-16%1

3 month return-19%2

YTD return+3%5

Mid term

Price vs 52wHigh77%5

1 year return+63%9

Long term

3 year return+47%5

5 year return-22%2

Risk Shield

Price Risk

Beta1.71

Volatility61%2

Free Cash Flow

Free Cash Flow Margin-406%1

Free Cash Flow Yield-15.2%1

Quality

ROCE-61%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

RCUSArcus Biosciences

Revenue FY25$247M

GROWTH RATING↗

WEAK32 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+30%10

Revenue, next 1Y-70%1

Revenue, next 3Y, CAGR-24%1

Revenue, next 5Y, CAGR+24%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 30%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

The runway holds up: revenue is set to grow 24%/yr over five years.10/10

WATCH

Revenue is set to shrink 24%/yr over the next 3 years, a little behind the market.4/10

WEAKNESSES

Growth is the weak spot here, trailing 68% of companies worldwide.

Revenue grew 30%/yr over the last 3 years, but it is set to shrink 24%/yr from here.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Maturing Grower

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK24 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-16%1

3-month return-19%2

YTD return+3%5

MID & LONG-TERM▾SCORE

% of 52-week high77%5

1-year return+63%9

3-year return+47%5

5-year return-22%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 63% over the past year, but 23% below its 52-week high. That is clearly ahead of the market.

WATCH

Returns sit at the market level so far this year (+3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+47% over three years and -22% over five), behind 60% of the market.

The stock is underperforming over the past month (-16%) and over three months (-19%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Arcus Biosciences, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

RCUSArcus Biosciences

Revenue FY25$247M

GROWTH RATING↗

WEAK32 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+30%10

Revenue, next 1Y-70%1

Revenue, next 3Y, CAGR-24%1

Revenue, next 5Y, CAGR+24%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28ELoss1

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 30%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

The runway holds up: revenue is set to grow 24%/yr over five years.10/10

WATCH

Revenue is set to shrink 24%/yr over the next 3 years, a little behind the market.4/10

WEAKNESSES

Growth is the weak spot here, trailing 68% of companies worldwide.

Revenue grew 30%/yr over the last 3 years, but it is set to shrink 24%/yr from here.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Maturing Grower

Growth is a weak point here: a business heading into decline. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK24 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-16%1

3-month return-19%2

YTD return+3%5

MID & LONG-TERM▾SCORE

% of 52-week high77%5

1-year return+63%9

3-year return+47%5

5-year return-22%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 63% over the past year, but 23% below its 52-week high. That is clearly ahead of the market.

WATCH

Returns sit at the market level so far this year (+3%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+47% over three years and -22% over five), behind 60% of the market.

The stock is underperforming over the past month (-16%) and over three months (-19%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Arcus Biosciences, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community